Synuclein-γ (SNCG) protein expression is associated with poor outcome in endometrial adenocarcinoma

Gynecologic Oncology

Volumn 124, Issue 1, 2012, Pages 148-152

  Mhawech Fauceglia, Paulette ^a   Wang, Dan ^a   Syriac, Susanna ^a   Godoy, Heidi ^a   Dupont, Nefertiti ^a   Liu, Song ^a   Odunsi, Kunle ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Clinical outcome; Endometrial adenocarcinoma; SNCG; Synuclein

Indexed keywords

GAMMA SYNUCLEIN; PARAFFIN;

ADULT; ADVERSE OUTCOME; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER INVASION; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; ENDOMETRIUM CARCINOMA; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TISSUE SECTION;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; ENDOMETRIAL NEOPLASMS; FEMALE; GAMMA-SYNUCLEIN; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM PROTEINS; PARAFFIN EMBEDDING; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 83055176510     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2011.09.037     Document Type: Article

References (25)

1. A. Jemal, R. Siegel, E. Ward, Y. Hao, J. Xu, and M.J. Thun Cancer statistics, 2009 CA Cancer J Clin 59 2009 225 249
2. H.C. Kitchener, and E.L. Trimble Endometrial cancer state of the science meeting Int J Gynecol Cancer 19 2009 134 140
3. R.W. Naumann Uterine papillary serous carcinoma: state of the state Curr Oncol Rep 10 2008 505 511
4. V. Benito, A. Lubrano, and O. Arencibia Pure papillary serous tumors of the endometrium: a clinicopathological analysis of 61 cases from a single institution Int J Gynecol Cancer 19 2009 1364 1369
5. J. Part Prognostic parameters of endometrial carcinoma Hum Pathol 35 2004 649 662
6. D.C. Figge, P.M. Otto, H.K. Tamimi, and B.E. Greer Treatment variables in the management of endometrial cancer Am J Obstet Gynecol 146 1983 495 500 (Pubitemid 13067477)
7. H.M. Keys, J.A. Roberts, and V.L. Brunetto A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study Gynecol Oncol 92 2004 744 751 (Pubitemid 38251372)
8. N. Bansal, V. Yendluri, and R.W. Wenham The molecular biology of endometrial cancers and the implications of pathogenesis, classification, and targeted therapies Cancer Control 16 2009 8 13
9. A. Doll, M. Abal, and M. Rigau Novel molecular profiles of endometrial cancer - new light through old windows J Steroid Biochem Mol Biol 108 2008 221 229 (Pubitemid 351179637)
10. H. Ji, Y.E. Liu, and T. Jia Identification of a breast cancer-specific gene, BCSG1, by different differential cDNA sequencing Cancer Res 57 1997 759 764 (Pubitemid 27085663)
11. K. Wu, Z. Weng, and Q. Tao Stage-specific expression of breast cancer-specific gene gamma-synuclein Cancer Epidemiol Biomarkers Prev 12 2003 920 925 (Pubitemid 37151530)
12. W. Bruening, B.I. Giasson, A.J. Klein-Szanto, V.M. Lee, J.Q. Trojanowski, and A.K. Godwin Synucleins are expressed in the majority of breast and ovarian carcinomas and in preneoplastic lesions of the ovary Cancer 88 2000 2154 2163 (Pubitemid 30233219)
13. Z. Li, G.M. Sclabas, and B. Peng Overexpression of synucelin-gamma in pancreatic adenocarcinoma Cancer 101 2004 58 65
14. Q. Ye, B. Feng, and Y.F. Peng Expression of γ-synucelin in colorectal cancer tissues and its role on colorectal cancer cell line HCT116 Worl J Gastroenterol 28 2009 5035 5043
15. M. Ahmad, S. Attoub, M.N. Singh, F.L. Martin, and O.M.A. El-Agnaf γ-Synuclein and the progression of cancer FASEB J 21 2007 3419 3430
16. T. Jia, Y.E. Liu, J. Liu, and Y.E. Shi Stimulation of breast cancer invasion and metastasis by synuclein gamma Cancer Res 59 1999 742 747 (Pubitemid 29076076)
17. P. Mhawech-Fauceglia, D. Wang, and J. Kesterson Gene expression profiles in stage I uterine serous carcinoma in comparison to grade 3 and grade 1 stage I endometrioid adenocarcinoma PLoS One 6 3 2011 Mar 23 e18066
18. W.T. Creasman Revision in classification by International Federation of Gynecology and Obstetrics Am J Obstet Gynecol 167 1992 857 858
19. J. Guo, C. Shou, and L. Meng Neuronal protein synuclein γ predicts poor outcome in breast cancer Int J Cancer 121 2007 1296 1305 (Pubitemid 47293797)
20. V.K. Singh, Y. Zhou, and J.A. Marsh Synuclein-γ targeting peptide inhibitor that enhances sensitivity of breast cancer cells to antimicrotubule drugs Cancer Res 67 2007 626 633 (Pubitemid 46192201)
21. I.G. Surgucheva, J.M. Sivak, M.E. Fini, R.E. Palazzo, and A.P. Surguchov Effect of gamma-synuclein overexpression on matrix metalloproteinases in retinoblastoma Y79 cells Arch Biochem Biophys 410 2003 167 176 (Pubitemid 36268809)
22. J. Morgan, A.V. Hoekstra, E. Chapman-Davis, J.L. Hardt, J.J. Kim, and B.M. Buttin Synuclein γ (SNCG) may be a novel prognostic biomarker in uterine papillary serous cracinoma Gynecol Oncol 114 2009 293 298
23. A.L. Blajeski, V.A. Phan, T.J. Kottle, and S.H. Kaufmann G(1) and G(2) cell cycle arrest following microtubule depolymerization in human breast cancers J Clin Invest 110 2002 91 99 (Pubitemid 34743469)
24. H.J. Shin, K.H. Baek, and A.H. Jeon Dual roles of human BubR1, a mitotic checkpoint kinase, in the monitoring of chromosomal instability Cancer Cell 4 2003 483 497
25. Z.Z. Pan, W. Bruening, B.I. Giasson, V.M. Lee, and A.K. Godwin Gamma-synuclein promotes cancer cell survival and inhibits stress- and chemotherapy drug-induced apoptosis by modulating MAPK pathways J Biol Chem 277 2002 35050 35060